Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PDL BioPharma transplant, autoimmune, antibodies news

PDLI plans to sell its commercial operations and shift its focus to discovering and developing antibodies to treat cancer and immunological diseases. PDLI's marketed products, which had

Read the full 273 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE